Skip to main content

Drug Interactions between dobutamine and Lumason

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DOBUTamine sulfur hexafluoride

Applies to: dobutamine and Lumason (sulfur hexafluoride)

MONITOR: Stress echocardiography with dobutamine can mimic an ischemic episode and increase the risk of rare but serious cardiopulmonary reactions associated with the use of sulfur hexafluoride and other ultrasound contrast agents. These reactions typically occur within 30 minutes of contrast administration, and the risk is increased in patients with cardiovascular instability such as recent acute coronary syndrome, unstable ischemia, evolving or ongoing myocardial infarction, angina at rest within last 7 days, recent coronary artery intervention, recent deterioration of ECG or laboratory/clinical findings, acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders.

MANAGEMENT: Sulfur hexafluoride may be used during stress echocardiography with dobutamine in patients who are in stable condition verified by the absence of chest pain or ECG modification during the two preceding days. However, vital signs, ECG, and blood pressure monitoring are recommended during and for at least 30 minutes after sulfur hexafluoride administration. Use of sulfur hexafluoride in patients with cardiovascular instability should only be undertaken after careful risk/benefit assessment and with close monitoring. Sulfur hexafluoride should not be used under circumstances where dobutamine is considered contraindicated.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. MHRA. Medicines and Healthcare Regulatory Agency (2014) SonoVue (sulphur hexafluoride). http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedic

Switch to consumer interaction data

Drug and food interactions

Moderate

DOBUTamine food

Applies to: dobutamine

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.